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Adverse events are frequent in nontuberculous mycobacteria 
pulmonary disease treatment, but evidence to support their 
management is scarce. An expert panel survey on management 
of adverse events shows consistent opinions on management of 
hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastroin-
testinal upset. These opinions can provide assistance in indi-
vidual patient management decisions.
Keywords.  antibiotic treatment; nontuberculous myco-
bacteria; adverse events; Mycobacterium avium complex; 
azithromycin.  
Treatment of Mycobacterium avium complex pulmonary di-
sease (MAC-PD) requires prolonged courses of potentially toxic 
antimicrobials and has suboptimal outcomes, with culture con-
version rates of 65% in patients treated for >1 year [1]. Across 
published cohorts, up to 70% of all treated patients reported a 
treatment-related adverse event (AE) [2–4] and 30%–70% of 
patients receiving daily antimicrobial treatment permanently 
discontinue at least 1 drug in their initial regimen because of 
AEs [2–4]. These regimen modifications may contribute to de-
velopment of macrolide resistance [5] or suboptimal outcomes.
There are very limited published data to support management 
decisions even for the most frequent AEs in MAC-PD treat-
ment, and management of drug toxicity is poorly addressed in 
current guidelines. To know the opinions of clinicians with ex-
pertise treating MAC-PD, we designed a survey on AE manage-
ment in MAC-PD, using the SurveyMonkey online tool (http://
www.surveymonkey.com). The survey presented common AEs 
in MAC-PD treatment (hepatotoxicity, ocular toxicity, gas-
trointestinal upset, tinnitus, and ototoxicity) and a choice of 
management strategies; the AEs were selected by a during a 
face-to-face meeting at the European Respiratory Society con-
ference (Paris, September 2018). Experts were selected from the 
Nontuberculous Mycobacteria Network European Trials Group 
(NTM-NET) (www.ntm-net.org) membership on basis of pub-
lication records of cohort studies of MAC-PD management. We 
sought to include experts from geographically diverse settings 
to capture the full range of opinions and underlying cultural 
differences and drug availabilities.
Twenty-three experts were identified and invited; 21 com-
pleted the survey. A summary of the questions and answers 
is presented in Table 1. The full questions and answers of the 
survey are available in the Supplementary Data.
There was almost unanimous agreement that mild, 
rifampicin-associated, alanine aminotransferase (ALT) and/
or aspartate aminotransferase (AST) elevations do not require 
action beyond ongoing surveillance; treatment interruption 
or a switch to a rifamycin-free regimen was preferred by 
most respondents only with severe hepatotoxicity (ALT and/
or AST concentrations >5 times the upper limit of normal). 
Hepatotoxicity, which may manifest as AST/ALT elevations 
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2 recent cohorts [4, 7]. This hepatotoxicity is mostly an idi-
osyncratic (ie, concentration/dose-independent) event, with 
spontaneous resolution and no recurrence after rifampicin 
reintroduction in >90% of MAC-PD patients [7], which mir-
rors previous experiences and recommendations in tubercu-
losis treatment [6].
Ocular toxicity by ethambutol was considered a reason to 
stop ethambutol or switch to another antibiotic class for 95% 
of the experts; 5% would interrupt and attempt a rechallenge. 
This aligns well with the available data. In 2 cohorts of MAC-PD 
treatment, ophthalmologist-confirmed ocular toxicity oc-
curred in 26 of 364 (8%) and 8 of 229 (3%) patients on daily 
Table 1. Summary of Survey Questions and Responses
Question Type Disease Severity Event Culprit Option Vote, %





Switch to rifabutin 0
Switch to other class 10





Switch to rifabutin 5
Switch to other class 30




Switch to other class 84




5 FC Severe Bloating/diarrhea Azithromycin Lower dose 21
Switch to clarithromycin 47
Switch to other class 5
Supportive Rx 26
6 FC Severe Slight hearing loss Amikacin Lower dosing frequency 70
Switch to ALIS 0
Stop amikacin 25
Switch to other class 5
Continue IV amikacin 0
7 NB Moderate Tinnitus Azithromycin Lower dose 65
Switch to clarithromycin 20
Switch to other class 0
Interrupt azithromycin 15
Continue regimen 0










Abbreviations: ALIS, amikacin liposome inhalation suspension; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FC, fibrocavitary; FQ, fluoroquinolone antibiotic; IV, intrave-
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ethambutol therapy (15 mg/kg/dose) [7, 8] and 0 of 90 patients 
on thrice-weekly dosing (25 mg/kg/dose) [8]. Yet, in the Griffith 
et al cohort, 99 of 229 patients (43%) had symptoms that war-
ranted an ophthalmology consult and 24 (10%) stopped eth-
ambutol at least temporarily [8]. The risk of ethambutol ocular 
toxicity increases with total drug exposure and thus it typically 
occurs late, that is, after >6 months, in therapy [7, 8]. Blurred 
vision and color vision disturbance are the most frequent mani-
festations, and these are mostly reversible after stopping eth-
ambutol; 4 patients were rechallenged with ethambutol thrice 
weekly (25 mg/kg/dose) and none developed recurrent ocular 
toxicity [8]. Stopping ethambutol without adding a third drug 
to the regimen occurs frequently [3, 5, 7], but is a known risk 
factor for development of macrolide resistance [5] and should 
be avoided.
Azithromycin was uniformly considered most likely re-
sponsible for bloating and diarrhea. Its management differed 
in the panel, with switching to clarithromycin, continuing 
azithromycin with supportive treatment, and lowering the 
azithromycin dose as the most frequent strategies. These strat-
egies evolve around maintaining macrolide therapy and high-
light the key role of macrolides in MAC-PD treatment [1]. 
Lowering azithromycin dose or offering supportive treatments 
(eg, nighttime administration, anti-emetics) both proved suc-
cessful in a previously published cohort [9]. Similarly, lowering 
the azithromycin dose or switching to clarithromycin were 
the preferred strategies for azithromycin treatment–emergent 
tinnitus (65% and 20% of votes). Tinnitus occurred in 18 and 
46% of patients in 2 cohorts of high-dose (500–600 mg/day) 
azithromycin therapy for MAC-PD [4, 9]. One study reported 
good outcome of lowering azithromycin doses from 600 mg to 
300 mg/day [9].
Lowering azithromycin doses may increase the risk of treat-
ment failure in patients with severe or fibrocavitary disease in 
whom regular doses may already be subtherapeutic [10, 11]. A 
switch to clarithromycin can be successful, but it is unproven 
whether this is due to clarithromycin causing less bloating and 
diarrhea or being less ototoxic [4, 9] or due to lower macrolide 
exposure because of shorter half-life and greater reduction in 
serum clarithromycin (68%) than azithromycin (23%) concen-
trations caused by rifampicin-induced cytochrome P450 me-
tabolism [10].
Ototoxicity with hearing loss is a notorious AE of parenteral 
aminoglycoside therapy and was observed in 42% (10/24) of 
patients treated with streptomycin and 27% (3/11) of patients 
treated with amikacin for macrolide-resistant MAC-PD [12]. 
Our panel preferred to lower the amikacin dosing frequency to 
thrice weekly or stop amikacin, as ototoxicity risk is associated 
with total aminoglycoside exposure. Switching to an alterna-
tive drug was not a common strategy, likely because no alter-
native drugs with proven efficacy in severe MAC-PD exist [5, 9, 
12]. Because aminoglycoside antimicrobial activity is exposure 
dependent [10], lower dosing is likely to negatively impact mi-
crobiologic outcomes. Switching to amikacin liposome inhala-
tion suspension (ALIS) or inhalation of conventional amikacin 
could be a rational strategy; in the CONVERT trial, only 10 
of 223 (4.5%) patients receiving ALIS reported hearing loss vs 
7 of 112 (6.3%) in the control arm [13]. However, the safety of 
switching to inhaled formulations of amikacin has not been in-
vestigated in the setting of proven amikacin ototoxicity.
The panel was also asked to rank 5 antimicrobials (amikacin, 
clofazimine, moxifloxacin, linezolid, and bedaquiline) as 
their preferred replacements for ethambutol and rifamycins; 
clofazimine and amikacin (or streptomycin) were preferred 
replacements for both the rifamycins and ethambutol. This se-
lection is in part driven by local availability and patient pref-
erences, particularly for clofazimine [4], but also reflects in 
vitro activity and in vivo treatment outcomes [4, 5, 9, 12]; the 
high ranking of the parenteral and toxic amikacin and strepto-
mycin emphasizes the limited options available. The outcome of 
MAC-PD treatment with regimens in which amikacin replaces 
rifampicin or ethambutol or in which clofazimine replaces eth-
ambutol has not been addressed in clinical studies.
This survey focused on MAC-PD treatment and only ad-
dressed a set number of AEs; several other important AEs (eg, 
vestibular toxicity, nephrotoxicity, and QTc interval prolonga-
tion) may arise during MAC-PD treatment [8, 10, 12]. Toxicities 
and outcomes are different in treatment of other nontuberculous 
mycobacterial (NTM) species (eg, Mycobacterium abscessus). 
Also, the members of the panel, while managing large num-
bers of NTM patients, are in frequent contact as members of 
numerous committees and projects. As a result, the topics ad-
dressed in the survey have likely been discussed previously 
between the experts, which may explain some of the level of 
agreement. This level of agreement contrasts with the very lim-
ited published data available to support these management 
decisions and a previous survey of other aspects of MAC-PD 
treatment where agreement among an expert panel was low 
[14].
In summary, this survey summarizes the opinions of 
MAC-PD experts on treatment-related AE management. 
Hepatoxicity of rifampicin was preferentially managed by 
watchful waiting or, if severe, interruption and reintroduc-
tion of normal doses. Azithromycin-associated diarrhea and 
tinnitus were preferentially managed by lowering the dose or 
switching to clarithromycin, with caveats. Ethambutol was dis-
continued in case of ocular toxicity; with careful monitoring, 
reintroduction using a thrice-weekly regimen might be safe in 
selected patients but our panel does not recommend this based 
on the low level of evidence and the potential associated risk. 
In the event of amikacin-induced hearing loss, the panel pre-
ferred lowering the dosing frequency or discontinuation. If ri-
fampicin or ethambutol needs to be discontinued, clofazimine 
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can provide assistance in clinical decision making, but should 
not be used as an alternative to expert consultation.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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